<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Lab Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Lab Med</journal-id>
      <journal-id journal-id-type="publisher-id">ALM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Laboratory Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2234-3806</issn>
      <issn pub-type="epub">2234-3814</issn>
      <publisher>
        <publisher-name>The Korean Society for Laboratory Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27374717</article-id>
      <article-id pub-id-type="pmc">4940495</article-id>
      <article-id pub-id-type="doi">10.3343/alm.2016.36.5.494</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
          <subj-group subj-group-type="subheading">
            <subject>Diagnostic Hematology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Acute Myeloid Leukemia With <italic>MLL</italic> Rearrangement and CD4+/CD56+ Expression can be Misdiagnosed as Blastic Plasmacytoid Dendritic Cell Neoplasm: Two Case Reports</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Ju-Mee</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kim</surname>
            <given-names>In-Suk</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lee</surname>
            <given-names>Jeong Nyeo</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Park</surname>
            <given-names>Sang Hyuk</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Hyung-Hoi</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chang</surname>
            <given-names>Chulhun L.</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Eun Yup</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Hye Ran</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oh</surname>
            <given-names>Seung Hwan</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Song</surname>
            <given-names>Sae Am</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Laboratory Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.</aff>
      <aff id="A2"><label>2</label>Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.</aff>
      <aff id="A3"><label>3</label>Department of Laboratory Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.</aff>
      <aff id="A4"><label>4</label>Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, Korea.</aff>
      <aff id="A5"><label>5</label>Department of Laboratory Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: In-Suk Kim. Department of Laboratory Medicine, Pusan National University Yangsan Hospital, 20 Geumo-ro, Mulgeum-eup, Yangsan 50612, Korea. Tel: +82-55-360-1878, Fax: +82-55-360-1880, <email>iskim0710@gmail.com</email></corresp>
        <corresp>Co-corresponding author: Jeong Nyeo Lee. Department of Laboratory Medicine, Haeundae Paik Hospital, Inje University, College of Medicine, 875 Haeun-daero, Haeundae-gu, Busan 48108, Korea. Tel: +82-51-797-3191, Fax: +82-51-797-3194, <email>jeong418@paik.ac.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <volume>36</volume>
      <issue>5</issue>
      <fpage>494</fpage>
      <lpage>497</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>12</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>4</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>6</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Korean Society for Laboratory Medicine.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <funding-group>
        <award-group>
          <funding-source country="KR">
            <institution-wrap>
              <institution>Pusan National University Hospital</institution>
              <institution-id institution-id-type="CrossRef">http://dx.doi.org/10.13039/501100008130</institution-id>
            </institution-wrap>
          </funding-source>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN), characterized by co-expression of CD4 and CD56 without any other lineage-specific markers, is an aggressive tumor type that shows a high frequency of skin involvement and nodal or marrow infiltration with a propensity toward leukemic dissemination [<xref rid="B1" ref-type="bibr">1</xref>].This disease was formerly defined by the World Health Organization as blastic NK-cell lymphoma, and was later grouped with AML and related precursor neoplasms [<xref rid="B2" ref-type="bibr">2</xref>]. Here we report two AML cases with <italic>KMT2A</italic> (or <italic>MLL</italic>) rearrangements along with CD4+/CD56+ expression, which had the potential to be misdiagnosed as BPDCN.</p>
    <p>A 59-yr-old man presented with erythematous papules and vesicles on his whole body for one week. Complete blood counts showed anemia (Hb, 80 g/L), thrombocytopenia (62&#xD7;10<sup>9</sup> platelets/L), and many circulating plasmoblast-like cells (65%). Bone marrow examination showed hypercellular marrow (90%) mostly composed of plasmoblast-like cells with coarse nuclear chromatin, distinct nucleoli, and abundant basophilic cytoplasm (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). Flow cytometry revealed that the neoplastic cells were positive for CD4, CD33, CD38, CD56, CD117, and CD138 (<xref ref-type="fig" rid="F1">Fig. 1B</xref>), and negative for other myeloid or lymphoid markers (<xref ref-type="table" rid="T1">Table 1</xref>). Skin lesions showed diffuse infiltration of medium- to large-sized agranular blastic cells with CD4 and CD56 co-expression (<xref ref-type="fig" rid="F1">Fig. 1C</xref>). Bone marrow and skin were negative for CD123 immunohistochemical stain. The chromosome study revealed 45,X,-Y[9]/46,XY[11] without 11q23 abnormalities. Multiplex, nested reverse transcription (RT)-PCR was performed for screening and detection of 28 chromosomal translocations using the HemaVision kit (DNA Technology, Research Park, Aarhus, Denmark), and the presence of <italic>MLL-MLLT10</italic> rearrangement was demonstrated. It was confirmed by direct sequencing (<xref ref-type="fig" rid="F1">Fig. 1D</xref>). Fluorescence <italic>in situ</italic> hybridization for <italic>MLL</italic> rearrangement revealed nuc ish(5'MLLx3,3'MLLx2)(5'MLL con 3'MLLx2)[170/200], suggesting the presence of an atypical <italic>MLL</italic> breakpoint. Although the lineage antigens expressed here were not specific to AML, he was diagnosed as having AML with <italic>MLL</italic> rearrangement in bone marrow and skin.</p>
    <p>A 30-yr-old woman presented with multiple lymphadenopathy for three weeks. Laboratory analysis revealed anemia (Hb, 81 g/L), thrombocytopenia (82&#xD7;10<sup>9</sup> platelets/L), and leukocytosis (16.77&#xD7;10<sup>9</sup> white blood cells/L) with circulating plasmacytoid cells (63%). Neither skin lesion nor monoclonal gammopathy was present. Bone marrow analysis showed hypercellular marrow (100%) with leukemic cells containing abundant basophilic cytoplasm (<xref ref-type="fig" rid="F1">Fig. 1E</xref>). Flow cytometry revealed that the neoplastic cells were positive for CD4, CD7, CD33, CD38, CD56, and CD64, (<xref ref-type="fig" rid="F1">Fig. 1F</xref>), and were negative for other markers (<xref ref-type="table" rid="T1">Table 1</xref>). The cytochemical stain for non-specific esterase in neoplastic cells was negative. Immunohistochemical stains of bone marrow biopsy specimens showed that the neoplastic cells were negative for CD123, CD138, kappa, and lambda. Lymph node biopsy analysis demonstrated that the neoplastic cells co-expressing CD4 and CD56 were negative for CD123. Cytogenetic analysis revealed 46,XX,t(9;11)(p22;q23),t(9;21)(q12;p11.2)[20]. The <italic>MLL-MLLT3</italic> rearrangement was detected by RT-PCR. Although adequate lineage-specific markers were not observed, she was diagnosed as having an AML with <italic>MLL</italic> rearrangement in bone marrow and lymph nodes.</p>
    <p>So far, three cases of CD4+/CD56+ hematologic malignancies with <italic>MLL</italic> rearrangements have been reported as rare cases of BPDCN with <italic>MLL</italic> rearrangement (<xref ref-type="table" rid="T1">Table 1</xref>). The leukemic cells reported in the literature expressed the myeloid and monocytic markers CD33, CD117, CD11c, CD15, or CD64, which were not specific enough to identify a specific lineage [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref>]. These three cases did not express highly specific plasmacytoid dendritic cell-associated antigens, such as CD123, TCL1, CD2AP, or CD303 (BDCA2); therefore, additional immunohistochemical studies were necessary at their diagnosis. Variable expression of CD4 or CD56 in adult AML cases with <italic>MLL</italic> rearrangement has been reported [<xref rid="B6" ref-type="bibr">6</xref>], and BPDCN is often confused with monocytic leukemias. Based on the limited information on immunophenotypes of these cases, <italic>MLL</italic>-related monocytic leukemia would be a reasonable diagnosis (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
    <p>This study emphasizes that the diagnosis of BPDCN should only be considered after a full investigation of plasmacytoid dendritic cell markers, ensuring there is no expression of myeloid or monocytic markers on the blasts [<xref rid="B7" ref-type="bibr">7</xref>]. Since hematologic neoplasms such as BPDCN, AML, extranodal NK/T cell lymphoma, nasal type, and mature T cell lymphomas with or without skin involvement may express CD56 with or without CD4, extensive immunohistochemical and genetic analyses are necessary before definitively diagnosing BPDCN or AML [<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref>].</p>
    <p>In conclusion, CD4+/CD56+ hematologic malignancies can be suspected to be BPDCN, and clinicians should conduct a full analysis including flow cytometry for adequate myeloid/monocytic markers, immunohistochemical stain for highly specific plasmacytoid dendritic cell-associated antigens, cytogenetic, and genetic studies to make an exact diagnosis and determine effective treatment.</p>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was supported by the yearly clinical research grant from Pusan National University Yangsan Hospital.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p><bold>Authors' Disclosures of Potential Conflicts of Interest:</bold> No potential conflicts of interest relevant to this article were reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garnache-Ottou</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Feuillard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Saas</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?</article-title>
          <source>Br J Haematol</source>
          <year>2007</year>
          <volume>136</volume>
          <fpage>539</fpage>
          <lpage>548</lpage>
          <pub-id pub-id-type="pmid">17367408</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Swerdlow</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <etal/>
          <source>WHO classification of tumours of haematopoietic and lymphoid tissues</source>
          <publisher-loc>France</publisher-loc>
          <publisher-name>IARC Press</publisher-name>
          <year>2008</year>
          <fpage>145</fpage>
          <lpage>147</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leung</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Au</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kwong</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>SY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CD4+/CD56+ hematologic malignancy with rearranged MLL gene</article-title>
          <source>Hum Pathol</source>
          <year>2006</year>
          <volume>37</volume>
          <fpage>247</fpage>
          <lpage>249</lpage>
          <pub-id pub-id-type="pmid">16426929</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toya</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Koya</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kandabashi</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The first case of blastic plasmacytoid dendritic cell neoplasm with <italic>MLL-ENL</italic> rearrangement</article-title>
          <source>Leuk Res</source>
          <year>2012</year>
          <volume>36</volume>
          <fpage>117</fpage>
          <lpage>118</lpage>
          <pub-id pub-id-type="pmid">21831428</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Huh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title><italic>KMT2A (MLL)-MLLT1</italic> rearrangement in blastic plasmacytoid dendritic cell neoplasm</article-title>
          <source>Cancer Genet</source>
          <year>2015</year>
          <volume>208</volume>
          <fpage>464</fpage>
          <lpage>467</lpage>
          <pub-id pub-id-type="pmid">26164398</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mu&#xF1;oz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nomded&#xE9;u</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Villamor</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Guardia</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Colomer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ribera</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute myeloid leukemia with <italic>MLL</italic> rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells</article-title>
          <source>Leukemia</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>76</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">12529663</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rush</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>DT</given-names>
            </name>
          </person-group>
          <article-title>Hematopathology HP 15-5</article-title>
          <source>ASCP case reports</source>
          <year>2015</year>
          <volume>HP 15-5</volume>
          <fpage>1</fpage>
          <lpage>20</lpage>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bekkenk</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Meijer</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Willemze</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature</article-title>
          <source>Ann Oncol</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>1097</fpage>
          <lpage>1108</lpage>
          <pub-id pub-id-type="pmid">15205205</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herling</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells</article-title>
          <source>Am J Clin Pathol</source>
          <year>2007</year>
          <volume>127</volume>
          <fpage>687</fpage>
          <lpage>700</lpage>
          <pub-id pub-id-type="pmid">17439829</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <title>Morphological features, flow cytometric analysis, immunohistochemical stain, and genetic study of the two cases of CD4+/CD56+AML. (A) Plasmoblast-like neoplastic cells in the first case (Wright Giemsa stain, 400&#xD7;, Bone marrow); (B) Immunophenotyping features with CD56 and CD4 coexpression in the first case; (C) Skin biopsy showing diffuse infiltration of medium- to large-sized agranular blastic cells into the dermis in the first case (Hematoxylin and Eosin stain, 100&#xD7;, Skin lesion); (D) The <italic>MLL-MLLT10</italic> rearrangement confirmed by direct sequencing in the first case; (E) Plasmacytoid cells in the second case (Wright Giemsa stain; &#xD7;400, Bone marrow); and (F) The immunophenotyping features with CD4 and CD56 coexpression in the second case.</title>
      </caption>
      <graphic xlink:href="alm-36-494-g001"/>
    </fig>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <title>The clinicopathologic characteristics of CD4+/CD56+ hematologic malignancies carrying the <italic>MLL</italic> rearrangement</title>
      </caption>
      <alternatives>
        <graphic xlink:href="alm-36-494-i001"/>
        <table frame="hsides" rules="rows">
          <col width="18.02%" span="1"/>
          <col width="16.47%" span="1"/>
          <col width="16.47%" span="1"/>
          <col width="16.47%" span="1"/>
          <col width="14.92%" span="1"/>
          <col width="17.64%" span="1"/>
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)"/>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">Case 1</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">Case 2</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">Case 3</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">Case 4</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">Case 5</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Reference</td>
              <td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B3" ref-type="bibr">3</xref>]</td>
              <td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B4" ref-type="bibr">4</xref>]</td>
              <td valign="top" align="center" rowspan="1" colspan="1">[<xref rid="B5" ref-type="bibr">5</xref>]</td>
              <td valign="top" align="center" rowspan="1" colspan="1">First case in this study</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Second case in this study</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Diagnosis</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">CD4+/CD56+ hematodermic malignancy</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">BPDCN with <italic>MLL-ENL</italic> rearrangement</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">BPDCN with <italic>MLL</italic> rearrangement</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">AML with <italic>MLL</italic> rearrangement</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">AML with <italic>MLL</italic> rearrangement</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Age/gender</td>
              <td valign="top" align="center" rowspan="1" colspan="1">50/F</td>
              <td valign="top" align="center" rowspan="1" colspan="1">45/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">8/F</td>
              <td valign="top" align="center" rowspan="1" colspan="1">59/M</td>
              <td valign="top" align="center" rowspan="1" colspan="1">30/F</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Race</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">China</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Japan</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Korea</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Korea</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Korea</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Chief complaint</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Not described</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Multiple disseminated skin nodules</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Mild fatigue and petechiae on extremities</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Multiple skin rash</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Multiple lymphadenopathy</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Skin lesion</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">No</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">No</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Circulating tumor cells</td>
              <td valign="top" align="center" rowspan="1" colspan="1">No</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Yes</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Bone marrow involvement</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Yes</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Yes</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Flow cytometric positivity</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CD4, CD45, CD56</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CD4, CD11c, CD33, CD45RA, CD56, CD68, CD117, CD123, HLA-DR</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CD4, CD15, CD33, CD56, CD64, CD117, HLA-DR, TdT</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CD4, CD33, CD38, CD45, CD56, CD117, CD138</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CD4, CD7, CD33, CD38, CD45, CD56, CD64,</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Flow cytometric negativity</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">CD2, CD3, CD5, CD7, CD8, CD10, CD13, CD14, CD19, CD20, CD22, CD23, CD34, HLA-DR, MPO</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">CD3, cCD3, CD5, CD7, CD8, CD10, CD11b, CD13, CD19, CD20, CD34, cMPO</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">CD2, CD3, cCD3, CD5, CD7, CD10, CD13, CD14, CD16, CD19, CD20, cCD22, CD34, cMPO</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">CD2, CD3, CD5, CD7, CD10, CD13, CD14, CD19, CD20, CD34, cMPO, TdT</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">CD3, CD5, CD8, CD10, CD11b, CD13, CD14, CD19, CD20, CD34, cCD79a, CD117, CD138, cMPO, kappa, lambda, TdT</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Karyotype</td>
              <td valign="top" align="center" rowspan="1" colspan="1">46, XX,t(4;9;11)(q12;p22;q23) [18]/46, XX [10]</td>
              <td valign="top" align="center" rowspan="1" colspan="1">49, XY, +add(1)(p13), +8, +8,t(11;19)(q23;p13.3)[20]</td>
              <td valign="top" align="center" rowspan="1" colspan="1">48,XX,+8,t(11;19)(q23;p13.3),+19[20]</td>
              <td valign="top" align="center" rowspan="1" colspan="1">45,X,-Y[9]/46,XY[11]</td>
              <td valign="top" align="center" rowspan="1" colspan="1">46,XX,t(9;11)(p22;q23),t(9;21)(q12;p11.2)[20]</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">FISH, <italic>MLL</italic> gene rearrangement</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Detected</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Detected</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Detected</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Detected atypical MLL breakpoint</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Detected</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">RT-PCR for <italic>MLL</italic></td>
              <td valign="top" align="center" rowspan="1" colspan="1">
                <italic>MLL-MLLT3</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">
                <italic>MLL-ELN</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">
                <italic>MLL-MLLT1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">
                <italic>MLL-MLLT10</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">
                <italic>MLL-MLLT3</italic>
              </td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Treatment</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">CHOP combination chemotherapy and allogeneic bone marrow transplantation</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">After failure of CHOP chemotherapy, acute leukemia-type chemotherapy was done</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Induction chemotherapy (daunorubicin, vincristine, prednisolone, and cytarabin)</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Induction chemotherapy (daunorubicin and cytarabin)</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Induction chemotherapy (daunorubicin and cytarabin) and allogeneic stem cell transplantation</td>
            </tr>
          </tbody>
        </table>
      </alternatives>
      <table-wrap-foot>
        <fn>
          <p>Abbreviations: BPDCN, blastic plasmacytoid dendritic cell neoplasm; RT-PCR, reverse transcription-PCR; cMPO, cytoplasmic myeloperoxidase; TdT, terminal deoxynucleotidyl transferase; CHOP, cyclophosphamide, vincristine, epirubicin, and prednisolone.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
